Form 8-K - Current report:
SEC Accession No. 0001213900-24-106240
Filing Date
2024-12-06
Accepted
2024-12-06 09:15:27
Documents
15
Period of Report
2024-12-02
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0223559-8k_cerotherap.htm   iXBRL 8-K 29921
2 PRESS RELEASE, DATED DECEMBER 6, 2024 ea022355901ex99-1_cero.htm EX-99.1 10332
  Complete submission text file 0001213900-24-106240.txt   264955

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE cero-20241202.xsd EX-101.SCH 3798
4 XBRL DEFINITION FILE cero-20241202_def.xml EX-101.DEF 26673
5 XBRL LABEL FILE cero-20241202_lab.xml EX-101.LAB 36817
6 XBRL PRESENTATION FILE cero-20241202_pre.xml EX-101.PRE 25297
17 EXTRACTED XBRL INSTANCE DOCUMENT ea0223559-8k_cerotherap_htm.xml XML 5942
Mailing Address 201 HASKINS WAY SUITE 230 SOUTH SAN FRANCISCO CA 94080
Business Address 201 HASKINS WAY SUITE 230 SOUTH SAN FRANCISCO CA 94080 650-407-2376
CERO THERAPEUTICS HOLDINGS, INC. (Filer) CIK: 0001870404 (see all company filings)

EIN.: 871088814 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40877 | Film No.: 241530710
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)